Document is current
Any future updates will be listed below
-
Authors
Pichailuck, Chenchit https://orcid.org/0000-0002-0153-2231
Kamolvit, Witchuda https://orcid.org/0000-0002-9135-6883
Phoonthong, Sethapong https://orcid.org/0009-0003-3687-2214
Aneklap, Payaow https://orcid.org/0009-0002-1257-2789
Neungton, Chanon https://orcid.org/0009-0000-6110-9614
Nitayanon, Perapon https://orcid.org/0000-0001-7964-7285
Tansirichaiya, Supathep https://orcid.org/0000-0002-4445-8529
-
Funding
Funding for this research was provided by:
Bayer, Thailand
- License Information
-
More Information
Article History
Received: 24 May 2026
Accepted: 24 June 2026
First Online: 30 June 2026
Declarations
:
: The study was reviewed and approved by the Siriraj Institutional Review Board, Faculty of Medicine Siriraj Hospital, Mahidol University (COA no. Si 654/2023). All participants provided written informed consent prior to enrolment. The trial was prospectively registered with the Thai Clinical Trials Registry on November 6, 2023 (TCTR20231106004; ), prior to the initial participant enrollment in December 2023. Written informed consent was obtained from all research participants. All procedures were conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: The authors declare no competing interests.
